循环TSP2作为2型糖尿病合并NAFLD患者肝纤维化的新型生物标志物
本研究在820例2型糖尿病合并NAFLD患者中,探讨血清TSP2水平与晚期纤维化(≥F3)的横断面及纵向关联。基线TSP2独立关联≥F3纤维化(OR 5.13,P<0.001),并可改善临床风险因素的识别能力;中位随访1.5年,8.8%发生≥F3纤维化,基线TSP2显著关联其发生(OR 2.82,P=0.005)。
要点
- 血清TSP2水平与2型糖尿病合并NAFLD患者晚期纤维化(≥F3)的存在独立相关。
- 基线TSP2可改善临床风险因素对≥F3纤维化的识别能力。
- 基线TSP2独立预测随访期间≥F3纤维化的发生(OR 2.82,P=0.005)。
核心结论
- 循环TSP2水平与晚期纤维化的存在及发生均相关,可能作为2型糖尿病合并NAFLD患者肝纤维化进展的预后生物标志物。
研究设计与样本
- 研究纳入820例2型糖尿病合并NAFLD患者,基线采用振动控制瞬时弹性成像(VCTE)评估肝脂肪变和纤维化。
- 对基线无晚期纤维化者进行VCTE复查,中位随访1.5年,采用多变量逻辑回归分析TSP2与≥F3纤维化的横断面及纵向关联。
主要发现
- 基线血清TSP2水平独立关联≥F3纤维化的存在(OR 5.13,P<0.001)。
- 纳入血清TSP2水平显著改善临床风险因素对≥F3纤维化的识别。
- 中位随访1.5年,8.8%的患者发生≥F3纤维化。
- 基线血清TSP2水平显著关联新发≥F3纤维化(OR 2.82,P=0.005),独立于BMI、血小板计数和基线CAP等风险因素。
临床怎么用
- 在2型糖尿病合并NAFLD患者中,可考虑检测血清TSP2以辅助识别晚期纤维化高风险者。
- 基线TSP2升高可能提示需加强肝纤维化进展的监测与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Preclinical studies have suggested that thrombospondin-2 (TSP2) is implicated in liver fibrosis. However, the clinical relevance of TSP2 in nonalcoholic fatty liver disease (NAFLD) remains undefined. Here, we investigated the cross-sectional and longitudinal associations of circulating TSP2 levels with advanced fibrosis (F3 or greater [≥FE] fibrosis) in NAFLD. RESEARCH DESIGN AND METHODS: Serum TSP2 levels were measured in 820 patients with type 2 diabetes and NAFLD. All participants received vibration-controlled transient elastography (VCTE) at baseline to evaluate their hepatic steatosis and fibrosis using controlled attenuation parameter (CAP) and liver stiffness (LS) measurements, respectively. Among those without advanced fibrosis at baseline, reassessment VCTE was performed to determine whether ≥F3 fibrosis had developed over time. Multivariable logistic regression analysis was used to evaluate the cross-sectional and longitudinal associations of serum TSP2 level with ≥F3 fibrosis. RESULTS: Baseline serum TSP2 level was independently associated with the presence of ≥F3 fibrosis (odds ratio [OR] 5.13, P < 0.001). The inclusion of serum TSP2 level significantly improved the identification of ≥F3 fibrosis by clinical risk factors. Over a median follow-up of 1.5 years, 8.8% developed ≥F3 fibrosis. Baseline serum TSP2 level was significantly associated with incident ≥F3 fibrosis (OR 2.82, P = 0.005), independent of other significant clinical risk factors of fibrosis progression, including BMI, platelet count, and CAP at baseline. CONCLUSIONS: Circulating TSP2 level was associated with both the presence and the development of advanced fibrosis and might be a potentially useful prognostic biomarker for the development and progression of liver fibrosis in patients with type 2 diabetes and NAFLD.
引用
- Lee CH, Seto WK, Lui DT, et al. Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. Diabetes Care. 2021. PMID: 34183428. doi:10.2337/dc21-0131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。